All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The vector of anti-GD2 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human GD2. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-GD2 antibody linked to 4-1BB and CD3ζ signaling domains. And the vector product was designed for the treatment of Neuroblastoma; melanoma.
CAR Construction : huK666 scfv-CD28-41BB-CD3ζ Fig.1 Stability of muK666 vs huK666 CARs. T-cells from 5 donors were transduced with equal titers of retroviral supernatant coding for muK666 or huK666 CARs. CAR expression was detected by anti-human-Fc polyclonal antibodies. MFI was identical in both constructs. Thomas, S., Straathof, K., Himoudi, N., Anderson, J., & Pule, M. (2016). An optimized GD2-targeting retroviral cassette for more potent and safer cellular therapy of neuroblastoma and other cancers. PLoS One, 11(3), e0152196. |
CAR Construction : huK666 scfv-CD28-41BB-CD3ζ Fig.2 Cytolytic activity of CAR T-cells were challenged with LAN-1 (a Neuroblastoma cell line expressing GD2) and A204 (a rhabdomyosarcoma cell line which is GD2 negative). Thomas, S., Straathof, K., Himoudi, N., Anderson, J., & Pule, M. (2016). An optimized GD2-targeting retroviral cassette for more potent and safer cellular therapy of neuroblastoma and other cancers. PLoS One, 11(3), e0152196. |
CAR Construction : huK666 scfv-CD28-41BB-CD3ζ Fig.3 Proliferation analysis of CAR T-cells were challenged with LAN-1 (a Neuroblastoma cell line expressing GD2) and A204 (a rhabdomyosarcoma cell line which is GD2 negative) at day 7. Thomas, S., Straathof, K., Himoudi, N., Anderson, J., & Pule, M. (2016). An optimized GD2-targeting retroviral cassette for more potent and safer cellular therapy of neuroblastoma and other cancers. PLoS One, 11(3), e0152196. |
CAR Construction : huK666 scfv-CD28-41BB-CD3ζ Fig.4 IFN-γ release analysis of CAR T-cells were challenged with LAN-1 (a Neuroblastoma cell line expressing GD2) and A204 (GD2 negative). Thomas, S., Straathof, K., Himoudi, N., Anderson, J., & Pule, M. (2016). An optimized GD2-targeting retroviral cassette for more potent and safer cellular therapy of neuroblastoma and other cancers. PLoS One, 11(3), e0152196. |
CAR Construction : huK666 scfv-CD28-41BB-CD3ζ Fig.5 IL-2 release analysis of CAR T-cells were challenged with LAN-1 (a Neuroblastoma cell line expressing GD2) and A204 (GD2 negative). Thomas, S., Straathof, K., Himoudi, N., Anderson, J., & Pule, M. (2016). An optimized GD2-targeting retroviral cassette for more potent and safer cellular therapy of neuroblastoma and other cancers. PLoS One, 11(3), e0152196. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-GD2 (hKM666) h(4-1BB-CD3ζ) CAR, pCDCAR1 (CAR-YF211). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION